Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary?
Tiliakos
Athan N
AN
Tiliakos
Nicholas A
NA
D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D004334:Drug Administration Schedule; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D016079:Refusal to Treat; D015423:Scleritis / Q000209:etiology* / Q000473:pathology; D016896:Treatment Outcome; D014606:Uveitis, Anterior / Q000209:etiology* / Q000473:pathology
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept